• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1278398 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type& \) b* H, c/ r, ~# y7 L
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
% ?! y; {6 U+ U. t, Y) d+ Author Affiliations
- s# c- l" U) V6 _
6 M) [# x# L: W' g# w% {4 k1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
! s- t: i3 W8 ]; z/ [2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' g7 s0 \) [4 r4 n( x, ~, m3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
/ [) g- R: Y6 }" ?. i8 q4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ) m0 [6 g) e3 V
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ' W+ S2 I2 k  p% y+ j; M6 A
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
& U3 O% t& R+ }( ]* d, ^7Kinki University School of Medicine, Osaka 589-8511, Japan
* p* r: X3 m( c7 ?! S/ m8Izumi Municipal Hospital, Osaka 594-0071, Japan * N' c$ E, B0 ~+ e5 ?8 {+ h0 N
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 4 u" c/ _& L) x6 G' ~. I
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
6 |6 `7 u" L/ z8 K6 H* C& qAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
; H& ^; O; k( {+ `* [1 Q  m- ~, P$ F$ Y" q& f- v
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type / i! k, K7 Y5 {% ]9 o/ y/ H; ~; @
- D% c. v7 G4 @2 H6 R$ G
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
2 a% j! {! i0 j$ C  C5 ]  M; W
. q9 w! R0 u, xAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  ! p6 a* k7 `/ s& ~
3 q5 `" V7 ?7 J! w) V) v
Published online on: Thursday, December 1, 2011 8 c7 m- }  V: C6 S1 s' N

8 c/ Q* D# P8 X& u) H  MDoi: 10.3892/ol.2011.507
- @9 n4 U3 t% c5 V  [- l  s8 m6 U7 g# S9 r
Pages: 405-410 ( u  r. Q, _; B1 h3 X) e) C4 l
# W5 z0 U$ B- t% ^3 _& w% }
Abstract:
5 M# [" v( r  H3 A/ gS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.9 D! Q$ `6 X# o
4 E3 j7 E( c& q; M3 O* G& \! q- C
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population1 c6 l" P; E/ o
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 4 [7 U, {/ e& j9 L
+ Author Affiliations
+ l+ ~; P, g% ?0 s1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
1 t: A/ Y8 W" x1 `+ }2Department of Thoracic Surgery, Kyoto University, Kyoto 2 U2 E* Y  d. T0 h
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan - A. C; S' {) `  Q' t# ?
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
& X+ N. V  B# u) _; e  m4 VReceived September 3, 2010.
! |/ |+ X5 t* A0 W( {, g2 ZRevision received November 11, 2010.
+ d3 D. d9 Z* \: pAccepted November 17, 2010. * g' G" \4 S7 l+ T* D
Abstract% c( A4 X6 m% M  O. t$ e2 K
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. # x1 |$ l8 x) b, Z) Y
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.   j& e! I1 R  O/ L9 j3 {1 }
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
) @3 b7 ?) e" L/ _Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. ' c. z5 r9 K7 g8 }" J
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
" M3 A- x. O; R8 H9 U4 q今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
, O$ f. J0 W* y  L* Y' R- m
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy$ _) ?& I" M- p/ \# F
http://clinicaltrials.gov/ct2/show/NCT01523587
% p, H0 o) ^- K, P& z. T. ~
3 j7 u# A+ L2 g) |BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
: D3 E) {+ T. \- n3 n" Ehttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 + h9 Y) z2 a+ c

! K. s9 ?4 \0 g/ k0 {从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。2 Z, ~2 x6 X3 \5 ?: ?5 J
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 , v. ~; J5 N7 W: I, _, D
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
; B2 O! |, H# B0 `至今为止,未出 ...

! r  T; Q2 T( {- b没有副作用是第一追求,效果显著是第二追求。
7 T7 |9 T& A3 d9 Q不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表